Enliven Therapeutics
(NASDAQ) ELVN
Enliven Therapeutics Financials at a Glance
Market Cap
$2.35B
Revenue (TTM)
$0.00
Net Income (TTM)
$103.69M
EPS (TTM)
$-1.86
P/E Ratio
-21.15
Dividend
$0.00
Beta (Volatility)
1.08 (Average)
Dividend
$0.00
Beta (Volatility)
1.08 (Average)
Price
$38.98
Volume
46,250
Open
$39.24
Price
$38.98
Volume
46,250
Open
$39.24
Previous Close
$38.98
Daily Range
$37.98 - $39.50
52-Week Range
$13.30 - $40.62
Dividend
$0.00
Beta (Volatility)
1.08 (Average)
Price
$38.98
Volume
46,250
Open
$39.24
Previous Close
$38.98
Daily Range
$37.98 - $39.50
52-Week Range
$13.30 - $40.62
ELVN News
ELVN: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Enliven Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
60
CEO
Richard A. Fair, MBA
Website
www.enliventherapeutics.comHeadquarters
Boulder, CO 80301, US
ELVN Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-27%
Return on Capital
-26%
Return on Assets
-22%
Earnings Yield
-4.73%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.35B
Shares Outstanding
59.80M
Volume
46.25K
Short Interest
0.00%
Avg. Volume
1.24M
Financials (TTM)
Gross Profit
$263.00K
Operating Income
$119.66M
EBITDA
$119.39M
Operating Cash Flow
$70.30M
Capital Expenditure
$158.00K
Free Cash Flow
$70.46M
Cash & ST Invst.
$462.62M
Total Debt
$399.00K
Enliven Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$46.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$2.35B
N/A
Market Cap/Employee
$37.90M
N/A
Employees
62
N/A
Net Income
$29.67M
-28.0%
EBITDA
$34.24M
-27.7%
Quarterly Fundamentals
Net Cash
$462.22M
+47.5%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$399.00K
N/A
Return on Assets
-21.78%
N/A
Return on Invested Capital
-26.04%
N/A
Free Cash Flow
$15.84M
+7.9%
Operating Cash Flow
$15.84M
+7.9%